These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31058504)

  • 21. How to Prepare a Compound Collection Prior to Virtual Screening.
    Bologa CG; Ursu O; Oprea TI
    Methods Mol Biol; 2019; 1939():119-138. PubMed ID: 30848459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening.
    Zuegg J; Cooper MA
    Curr Top Med Chem; 2012; 12(14):1500-13. PubMed ID: 22827520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The integration of pharmacophore-based 3D QSAR modeling and virtual screening in safety profiling: A case study to identify antagonistic activities against adenosine receptor, A2A, using 1,897 known drugs.
    Fan F; Toledo Warshaviak D; Hamadeh HK; Dunn RT
    PLoS One; 2019; 14(1):e0204378. PubMed ID: 30605479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compound optimization through data set-dependent chemical transformations.
    de la Vega de León A; Bajorath J
    J Chem Inf Model; 2013 Jun; 53(6):1263-71. PubMed ID: 23654345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expanding the medicinally relevant chemical space with compound libraries.
    López-Vallejo F; Giulianotti MA; Houghten RA; Medina-Franco JL
    Drug Discov Today; 2012 Jul; 17(13-14):718-26. PubMed ID: 22515962
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictions of BuChE inhibitors using support vector machine and naive Bayesian classification techniques in drug discovery.
    Fang J; Yang R; Gao L; Zhou D; Yang S; Liu AL; Du GH
    J Chem Inf Model; 2013 Nov; 53(11):3009-20. PubMed ID: 24144102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Target-based drug discovery through inversion of quantitative structure-drug-property relationships and molecular simulation: CA IX-sulphonamide complexes.
    Žuvela P; Liu JJ; Yi M; Pomastowski PP; Sagandykova G; Belka M; David J; Bączek T; Szafrański K; Żołnowska B; Sławiński J; Supuran CT; Wong MW; Buszewski B
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1430-1443. PubMed ID: 30220229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Development of a Weighted Index to Optimise Compound Libraries for High Throughput Screening.
    Eurtivong C; Reynisson J
    Mol Inform; 2019 Mar; 38(3):e1800068. PubMed ID: 30345657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative structure/activity relationship modelling of pharmacokinetic properties using genetic algorithm-combined partial least squares method.
    Yamashita F; Fujiwara S; Wanchana S; Hashida M
    J Drug Target; 2006; 14(7):496-504. PubMed ID: 17062396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Automated Inference of Chemical Discriminants of Biological Activity.
    Raschka S; Scott AM; Huertas M; Li W; Kuhn LA
    Methods Mol Biol; 2018; 1762():307-338. PubMed ID: 29594779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bayesian models trained with HTS data for predicting β-haematin inhibition and in vitro antimalarial activity.
    Wicht KJ; Combrinck JM; Smith PJ; Egan TJ
    Bioorg Med Chem; 2015 Aug; 23(16):5210-7. PubMed ID: 25573118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small molecules and their role in effective preclinical target validation.
    Clegg MA; Tomkinson NC; Prinjha RK; Humphreys PG
    Future Med Chem; 2017 Sep; 9(14):1579-1582. PubMed ID: 28828889
    [No Abstract]   [Full Text] [Related]  

  • 33. Discovering Highly Potent Molecules from an Initial Set of Inactives Using Iterative Screening.
    Cortés-Ciriano I; Firth NC; Bender A; Watson O
    J Chem Inf Model; 2018 Sep; 58(9):2000-2014. PubMed ID: 30130102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico estimation of basic activity-relevant parameters for a set of drug absorption promoters.
    Bak A; Kozik V; Smolinski A; Jampilek J
    SAR QSAR Environ Res; 2017 Jun; 28(6):427-449. PubMed ID: 28573881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of QSAR and shape pharmacophore modeling approaches for targeted chemical library design.
    Ebalunode JO; Zheng W; Tropsha A
    Methods Mol Biol; 2011; 685():111-33. PubMed ID: 20981521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple machine learning based descriptive and predictive workflow for the identification of potential PTP1B inhibitors.
    Chandra S; Pandey J; Tamrakar AK; Siddiqi MI
    J Mol Graph Model; 2017 Jan; 71():242-256. PubMed ID: 28006676
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Method for Systematic Analogue Search Using the Mega SAR Matrix Database.
    Yoshimori A; Horita Y; Tanoue T; Bajorath J
    J Chem Inf Model; 2019 Sep; 59(9):3727-3734. PubMed ID: 31468964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative analysis of machine learning methods in ligand-based virtual screening of large compound libraries.
    Ma XH; Jia J; Zhu F; Xue Y; Li ZR; Chen YZ
    Comb Chem High Throughput Screen; 2009 May; 12(4):344-57. PubMed ID: 19442064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integrating virtual screening and combinatorial chemistry for accelerated drug discovery.
    López-Vallejo F; Caulfield T; Martínez-Mayorga K; Giulianotti MA; Nefzi A; Houghten RA; Medina-Franco JL
    Comb Chem High Throughput Screen; 2011 Jul; 14(6):475-87. PubMed ID: 21521151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative structure/property relationship analysis on aqueous solubility using genetic algorithm-combined partial least squares method.
    Wanchana S; Yamashita F; Hashida M
    Pharmazie; 2002 Feb; 57(2):127-9. PubMed ID: 11878188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.